TransMedics Group (NASDAQ:TMDX) Upgraded by Baird R W to “Strong-Buy”

Baird R W upgraded shares of TransMedics Group (NASDAQ:TMDX) to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley boosted their target price on TransMedics Group from $104.00 to $145.00 and gave the company an equal weight rating in a research note on Monday, July 15th. Cantor Fitzgerald began coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They issued an overweight rating and a $161.00 price objective on the stock. Oppenheimer raised their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an outperform rating in a research report on Thursday, August 1st. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a buy rating in a research report on Thursday, August 1st. Finally, Stephens raised their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an overweight rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Buy and an average price target of $174.30.

TransMedics Group Stock Up 10.1 %

Shares of TMDX stock opened at $159.14 on Tuesday. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The firm has a fifty day moving average of $156.02 and a 200-day moving average of $130.87. The company has a market capitalization of $5.31 billion, a price-to-earnings ratio of -460.00 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s revenue was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) EPS. As a group, equities research analysts predict that TransMedics Group will post 1.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,247 shares of company stock valued at $9,650,880. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of TMDX. Fidelis Capital Partners LLC bought a new position in TransMedics Group in the 1st quarter valued at about $35,000. International Assets Investment Management LLC bought a new position in TransMedics Group in the second quarter valued at approximately $47,000. J.Safra Asset Management Corp increased its stake in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares during the last quarter. Signaturefd LLC raised its position in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Amalgamated Bank lifted its stake in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.